Malignant mesothelioma, developed in the thoracic cavity, is resistant to current treatments. Suppression of the local tumor growth is beneficial to the patients since mesothelioma infrequently metastasizes to extrapleural organs. A majority of the tumors have a homologous genetic deletion at the INK4A/ARF locus that includes the p14 ARF and the p16 INK4A genes, and the genetic defect results in an inactivation of the p53-mediated pathways and in progression of cell cycle through pRb phosphorylation. Preclinical studies targeting the genetic abnormality with adenoviruses showed that restoration of the p53 pathways induced pRb dephosphorylation and subsequently produced anti-tumor effects. A number of preclinical studies with different genes and vector systems demonstrated the therapeutic efficacy and raised the possibility of gene therapy in clinical settings. An intrapleural administration of vectors has several advantages in transducing pleural mesothelioma but activates rapid antibody production which impedes further gene expression. There have been several clinical studies conducted for mesothelioma and these trials showed the feasibility of intrapleural administrations of adenovirus vectors. In this review we summarize major preclinical and clinical gene therapy for mesothelioma, and discuss the advantages of gene therapy in the context of stimulating host immune systems. Accumulating clinical data suggest that an intrapleural administration of viral vectors has distinct aspects which are not observed in other administration routes.
INTRODUCTION
Malignant mesothelioma is relatively rare cancer developed from mesothelium that covers the pleural and the peritoneal cavity. Pleural mesothelioma is the most common type, about 75 percent of the cases, and peritoneal mesothelioma is the second in the frequency. Extrapleural and extraperitoneal metastases are infrequent and most of the cases extend locally. Pleural mesothelioma invades into the vicinity and disturbs functions of vital organs such as lungs, large vessels and heart, which results in respiratory failure, massive pleural effusion, cardiac tamponade and spinal cord compression. The signs and symptoms found in the patients such as cough and chest pain are not specific to mesothelioma and diagnosis at the early phase is often difficult.
Mesothelioma is often linked with occupational asbestos exposure but is less frequently caused by non-asbestos substance as well such as erionite, wool-like fibrous mineral found in volcanic ash. 1, 2 Many industrial countries had used asbestos for years but the usage has been already inhibited in these regions. In contrast, emerging countries do not have a strict legal regulation on asbestos usage and amounts of industrial consumption in these countries are increasing. Epidemiological analyses based on the amounts of asbestos utilized predict an increasing number of the patients not only in industrialized Western countries but in economic emerging nations particularly in Asia. 3 The latent period of mesothelioma after asbestos exposure is long, more than 30 years in average, and any medical procedures to prevent the development are not currently known. Detection of mesothelioma in an early stage is difficult because it is often asymptomatic, and differential diagnosis from other diseases is not easy. Moreover, mesothelioma is resistant to current therapeutics despite recent multimodal treatments. 1, 4 Extrapleural pneumonectomy is one of the standard surgical procedures but it can be applicable only to an early-staged case. The recurrence is common even after such a radical operation and post-surgical chemotherapy. Mesothelioma is essentially resistant to radiotherapy and it is thereby used mainly for a palliative purpose at present. Systemic chemotherapy is the primary treatment in most of the cases, and a combination of cisplatin (CDDP) and pemetrexed (PEM) is the current first-line chemotherapy regimen. 5 Nevertheless, a mean survival rate with the CDDP plus PEM combination is only 12.1 months. 5 Other possible chemotherapy regimens have been tested but the clinical benefits has not been as great as those with the first-line agents. A novel therapeutic strategy is required to improve the prognosis and quality of life for the patients as well as to deal with the growing number of the patients worldwide.
Gene therapy can be one of the potential therapeutics for mesothelioma since it develops in the closed cavity. Intrapleural administration of vectors is technically feasible even in aged patients when they have pleural effusion. Constant lung movements accompanied by respiration can facilitate vector distribution within the pleural cavity. Mesothelioma uncommonly metastasizes to extrapleural regions and control of tumor extension within the cavity is thereby beneficial to the patients.experimental gene therapy were effective to suppress the local tumor growth, and several clinical trials with adenovirus (Ad) vectors have shown the fesibility. [6] [7] [8] [9] [10] [11] [12] This review summarizes preclinical studies with different therapeutic directions and clinical trials with replication-incompetent Ad, and discuss a potential of gene therapy for pleural mesothelioma (Figure 1 ).
PRECLINICAL STUDY
(1) Targeting mesothelioma-associated gene defects Genetic analyses revealed a characteristic defect in mesothelioma. About 70-80% of the clinical specimens from mesothelioma patients lacked the INK4A/ARF genetic locus containing the p16 INK4A and the p14 ARF genes, while the majority of specimens possessed the wild-type p53 gene. 13 Defective p16 functions in mesothelioma result in an enhanced cyclin-dependent kinase (CDK) 4/6 activity, which subsequently phosphorylates pRb and promotes cell cycle progression ( Figure 2 ). The p14 deficiency augments the MDM2 activity that induces p53 degradation through an ubiquitination process, and consequently decreases p53-mediated actions. The functional loss of p53 downstream pathways renders mesothelioma cells resistant to apoptotic cell death. Reintroduction of the defective genes in mesothelioma is a possible therapeutic approach through functional restoration of the two major suppressor genes.
Transduction of mesothelioma with an Ad vector bearing the p14 or the p16 gene (Ad-p14, Ad-p16) suppressed the cell proliferation through pRb dephosphorylation, and reactivation of p53-mediated checkpoints mechanisms. [14] [15] [16] [17] Expressed p14 in the INK4A/ARF-deficient mesothelioma up-regulated p53 expression levels, and consequently induced cell cycle arrest at G1 phase and apoptosis thereafter when the p53 downstream pathways were intact. 15 Introduction of the p14 gene also dephosphorylated pRb through induction of p21, one of the p53 target molecules, and contributed to the inhibited cell growth. Interestingly, transduction with Ad-p14 did not fully activate the p53-mediated signal transduction although the precise mechanism remained unknown. 16 These data collectively suggested a pivotal role of p14 in cell death of mesothelioma, but efficacy of gene therapy targeting p14 is influenced by other genetic conditions of host cells. Furthermore, Ad-p14-mediated anti-tumor effects in vivo have not been demonstrated. Ad-p16 also decreased the phosphorylation level of pRb through inhibited CDK4/6 activities, and induced cell cycle arrest at G1 phase in the transduced mesothelioma cells. The forced p16 expression then induced apoptotic cell death and inhibited cell growth in vivo as well. 14, 17 Experimental data showed that Ad-p16 produced better therapeutic effects than Ad-p14 in mesothelioma. 18, 19 Interestingly, a combinatory use of Ad-p14 and Ad-p16 produced less anti-tumor effects than an individual Ad administration although a mechanism of the antagonistic action remain uncharacterized. 19 Reactivation of the p53 pathways with Ad-p53 is also a therapeutic strategy and is a direct way to reconstitute all the p53 signal pathways in contrast to Ad-p14 or Ad-p16. In addition, expressed p53 dephosphorylated pRb through up-regulated p21. A number of studies demonstrated that Ad-p53-mediated anti-tumor effects were in general difficult to be achieved in wild-type p53-bearing tumors compared with those with p53 mutations, 20 which was attributable to empirical data that tumors with the wild-type p53 gene tended to have defects in the p53 downstream pathways. Giuliano et al. firstly reported that Ad-p53 transduction suppressed growth of mesothelioma 21 but no further precise analyses had been conducted. Recently Li et al. clarified the mechanism how overexpressed p53 induced growth inhibition in p14/p16-defective mesothelioma cells. 22 Ad-p53-mediated transduction induced phosphorylation of p53 at serine 15 and 46 residues, both of which are makers for activated p53 pathways, and augmented expression levels of p53 target molecules including MDM2. Extrinsic but not intrinsic apoptotic pathways were activated through an enhanced expression of the Fas and the TRAIL receptors. Activated p53 pathways further induced synergistic cytotoxicity with the firstline chemotherapeutic agents, CDDP and PEM, which was also evidenced in an orthotopic animal model. 22 These reports collectively suggested that the p53 downstream pathways were intact in mesothelioma and that restoration of the p53 functions was a cornerstone for mesothelioma treatments through cell cycle arrest followed by apoptosis.
A combinatory use with a p53-activating agent is one of the directions to extend application of Ad-p53. A chemical agent that Figure 2 . Deletion of the p14 ARF and the p16 INK4A genes in mesothelioma. The p14 and the p16 genes, localized in the chromosome 9p21, are differentially transcribed from the INK4A/ ARF region and these products negatively regulate p53 and pRb functions through inhibition of MDM2 and cyclin-CDK complexes. Defective p14 facilitates p53 degradation through proteasome pathways since p14 suppresses the MDM2 activity that mediates p53 ubiquitination processes. p16 and p21 inhibit functions of the cyclin D-CDK4/6 and the cyclin E-CDK2 complex, respectively, and both of the complexes mediates pRb phosphorylation. Deletion of the INK4A/ARF region in mesothelioma thereby induces constant cell cycle progression without p53-mediated checkpoint mechanisms.
inhibits the interaction between p53 and MDM2 can block p53 degradation processes and consequently up-regulate p53 expression levels. Nutlin-3 is a representative small molecule to suppress the MDM2-p53 interactions and p53 ubiquitination, and preferentially inhibits proliferation of p53-wild type but not p53-mutated tumors. Our preliminary data showed that Ad-p53 together with such a p53-activating agent produced combinatory cytotoxic activities on mesothelioma. These possible combinations circumvent vector-mediated and chemical agent-induced adverse effects by decreasing respective usage doses, and can be an option in a future clinical application.
(2) Gene therapy targeting signal transduction Biochemical analyses demonstrated aberrant growth signaling and enhanced angiogenesis in mesothelioma, which makes the relevant molecules targets for the treatments. Mesothelioma often showed elevated expression of both vascular endothelial growth factor (VEGF) and the receptors, VEGFR-1 and VEGFR-2. 13, 23 Furthermore, expression levels of hepatocyte growth factor (HGF) and the receptor c-Met are also up-regulated in the majority of mesothelioma specimens. 24 Previous studies showed that the HGF/c-Met pathway had a crucial role in invasion of tumors and in metastasis, and demonstrated that inhibition of the pathway suppressed tumor infiltration into neighboring tissues. 25 A N-terminal fragment of a chain of HGF, named as NK4, is a secretary molecule with a binding activity to the c-Met receptor.
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NK4 protein is thereby a natural competitive antagonist of HGF and in fact blocks the HGF/c-Met signal transduction. Interestingly, NK4 also inhibits angiogenesis by suppressing the VEGF-mediated pathways although the precise mechanism is not completely understood. Recently, Sakai et al. demonstrated that extracellular NK4 bound to perlecan, a multi-domain heparin sulfate proteoglycan that interacts with basement membrane components. 26 The NK4/perlecan interactions subsequently impairs fibronectin assembly and produce inhibitory actions on an anchoragedependent signaling and angiogenesis. NK4 does not directly block the interaction between VEGF and the receptors but rather indirectly suppresses the VEGF-mediated angiogenic environments. Biological activities of NK4 and the production in vivo are not well understood, but NK4 seems to be harmless to normal tissues since a certain amount of NK4 is detected under a physiological condition. In addition, a half life of NK4 protein in vivo is relatively short, which suggests that continuous NK4 production at a local site is preferable for better therapeutic effects rather than a systemic administration of NK4 protein. The majority of mesothelioma do not have any genetic mutations at the c-Met locus and a few mutated c-Met cases which were identified in the clinical specimens showed that the mutated forms were not constitutively active in stimulating the downstream signal pathways. These data collectively suggest that NK4 is one of the candidates to be tested for the therapeutic efficacy as gene medicine. A number of preclinical studies in fact demonstrated that Ad expressing the NK4 gene (Ad-NK4) produced anti-tumor effects against many types of tumors including mesothelioma. 27 Transduction of mesothelioma with Ad-NK4 inhibited HGF-mediated phosphorylation of c-Met and the cell migration. Injection of Ad-NK4 into subcutaneous mesothelioma retarded the subsequent tumor growth. Based on these preclinical studies, we are currently preparing a clinical trial for chemotherapy-failed mesothelioma patients to examine the safety of an intrapleural injection of Ad-NK4.
(3) Oncolytic virotherapy A number of oncolytic viruses, which replicate preferentially within tumors, have been examined for their cytotoxicity and efficacy in mesothelioma, such as Ad, 28, 29 measles, 30, 31 retroviruses, 32 Newcastle disease, 33 herpes simplex viruses, 34 vesicular stomatitis virus 35 and Sendai viruses. 36 The cytotoxic actions of these oncolytic viruses were not specific to mesothelioma and were demonstrated in other tumor types as well. Advantages and disadvantages of the viruses-mediated oncolysis which were shown in other tumors are also applicable to mesothelioma. It is often difficult to achieve sufficient anti-tumor effects with these oncolytic viruses as monotherapy. The viruses have thereby been modified in the structure to enhance the cytotoxicity. Switching of the receptor binding sites from conventional type 5 Ad to the other types can increase Ad infectivity. Some of mesothelioma express the coxsachie adenovirus receptor (CAR) molecules, the major type 5 Ad receptors, at a low level. Consequently, substitution of the fiber-knob region which mediates a binding to CAR with that of type 35 Ad improves the infectivity to mesothelioma since CD46, the major type 35 Ad receptors, 37 is expressed at a high level in a number of mesothelioma cells. 38 This modification increased the Ad infectivity to target tumors but such changes of Ad tropisms might also augment unwanted infection to normal surrounding tissues since CD46 is expressed on many cell types. A system to ensure tumor-specific viral replication becomes essential for the safety of the chimeric Ad. Activating viral transcriptions under a regulatory region of the gene that is preferentially transcribed in target tumors is commonly used for the tumor specificity. It is however more important to boost antitumor effects in a clinical setting than to reduce a risk of widespread infection since the major drawback of current gene medicine is an insufficient cytotoxic ability. Ad replication is essentially dependent on growth of the infected cells, and normal tissues, which are less active in cell proliferation compared with tumors, can inefficiently support viral replication. The Admediated cytotoxicity itself is thus greater in tumors than in non-tumorous cells even without any specific designs for tumorspecific replication. Subsequently, some scientists presume that oncolytic viruses currently tested need further cytotoxicity rather than tumor-specific replication.
Co-expression of enzymes that destroy extracellular matrix such as relaxin 39 and heparanase 40 in target tumors facilitates virus spread within the tumor nests. This approach is particularly important for mesothelioma since fibrous tissues are accumulated in mesothelioma during the tumor extension within the thoracic cavity. Elevated TGF-b secretion from mesothelioma is partly responsible for enhanced stroma formation. 41 Accumulation of such extracellular matrixes and tumor-associated fibrous tissues surrounding and within mesothelioma hampers spread of viruses released from infected tumors. These enzymes digest the matrix in tumorous and non-tumorous tissues, which facilitates viral spreading without interfering viral replication ability. The enzymatic activities might promote metastasis by enhancing release of tumor cells from the nest, but as far as mesothelioma is concerned, distant metastasis to extrapleural organs is uncommon. Retention of the enzymes in a closed cavity favors further digestion of extracellular matrix. In addition, combination of oncolytic viruses and conventional anti-cancer agents or perhaps radiation as well achieves greater anti-tumor effects than monotherapy. Radiation to a wide region of chest is not recommendable due to a risk of radiation-induced pneumonitis, but intensity modulated radiation therapy can circumvent the adverse effect. The new radiation technique, which can focus the energy on tumor sites and reduce radiation to non-target organs, comes to be used in combination with chemotherapy. A possible combination with chemotherapy and radiotherapy will be an option for gene therapy in future.
CLINICAL STUDY OF GENE THERAPY FOR MESOTHELIOMA
There have been conducted 5 clinical trials, including 4 phase I and 1 pilot studies, with replication-incompetent Ad for pleural mesothelioma patients (Table 1 ). In addition, 1 pilot study with Gene therapy for mesothelioma M Tagawa et al vaccinia viruses was performed. Some mesothelioma patients were also included in different clinical case studies, which were aimed to treat advanced cancer patients or those with malignant pleural effusions. 42, 43 These case studies reported 2 mesothelioma patients that were treated with oncolytic Ad armed with the granulocyte macrophage colony-stimulating factor gene 42 and 8 patients treated with Ad-p53 together with radiofrequency hyperthermia. 43 Detailed clinical data and outcomes of these non-phase I studies were unavailable. In contrast, 4 clinical studies that were conducted in Pennsylvania University, including 3 phase I trials and 1 pilot study, [9] [10] [11] [12] were informative. Their first phase I trial was a dose escalation study with Ad expressing the herpes simplex virus-thymidine kinase gene (Ad-HSV-TK), with the maximum dose up to 5 Â 10 13 virus particles (vp). 9 Ad-HSV-TK diluted with saline were administered into the pleural cavity and the patients were then injected with a prodrug, ganciclovir, intravenously. The adverse effects were relatively minimal with transient fever and a low-level elevation of serum transaminases, and the patients in fact well tolerated to the Ad administration. Antibody against Ad was however produced in all the cases and reached to the maximal level 15-20 days after the administration. Preexisting antibody levels in those patients were low in general and biopsy specimens after Ad administration demonstrated transduction of the HSV-TK gene in the tumors. The transgene expression was however detected only when a high dose of Ad, more than 1.6 Â 10 13 vp, was administered, and was identified only at superficial cell layers of the tumor tissues. Nevertheless, overall clinical responses were greater than the estimation judged on the gene transduction efficacy. Notably, the study reported 3 long survived cases who did not receive any chemotherapeutic agents thereafter. The follow-up study demonstrated that these good clinical responses with obvious tumor regression became evident a few months after the Ad administration, suggesting that the anti-tumor effects were attributable to possible systemic immune responses. In addition, Sterman et al. detected antibody in the post-treatment sera which recognized unidentified molecules that were expressed in several human mesothelioma cell lines. 9 The molecular sizes that antibody reacted were different among the respective patients, and these molecules were not detected in pre-treatment sera of the same patients. These data collectively suggest that the suicide gene therapy evoked immune responses against putative tumor antigen(s) which could be shared among human mesothelioma. There was no direct evidence that antibody recognizing the shared antigen(s) contributed to the anti-tumor effects. Nevertheless, generation of such antibody suggested induction of cell-mediated immunity in the same patients since helper T cells, involved in either humoral or cellular immune responses, were activated by the same major histocompatibility complex (MHC) class II-binding peptides. The subsequent study further characterized these immune responses in terms of antibody formation. 44 An intrapleural injection of Ad generated neutralizing antibody not only against Ad structural proteins but against the HSV-TK transgene. Morever, the antibody level in the pleural effusion was the same as that in the serum. Peripheral T cells proliferated after a single Ad injection, suggesting that T cells in general populations were already primed with Ad probably due to previous respiratory infections. These immune responses did not induce serious adverse reactions, and pre-existing humoral and cellular immunity prior to the Ad administration did not inhibit subsequent Ad-mediated gene transduction. The clinical studies collectively indicated that direct cytotoxicity by the suicide gene therapy was rather minimal but immune responses, perhaps being mediated by cytotoxic T cells and less significantly by natural killer cells, were responsible for the good clinical outcomes.
The second type of phase I studies in Pennsylvania was an intrapleural injection of Ad bearing the interferon genes (Ad-IFN). [10] [11] [12] These clinical trials for mesothelioma were the first in a human case to use the IFN genes for gene therapy. IFNs have multiple functions in the context of anti-tumor activities, such as augmented expression of the MHC class I antigens and induction of apoptosis. The clinical studies showed that the maximal tolerance dose of Ad-IFN-b in the pleural cavity was about 1 Â 10 12 vp, a smaller dose than that used in the Ad-HSV-TK trials because the expressed IFN-b itself produced adverse effects. The transgene expression was nevertheless more frequently demonstrated in mesothelioma than the cases with Ad-HSV-TK, which may be due to differential detection systems of respective gene products. IFN-b augmented host immune responses, which was evidenced by activation of natural killer cells and by production of antibody against mesothelin, a molecule expressed preferentially in mesothelial cells, the SV40 T antigen and uncharacterized putative tumor antigens. Viral shedding was also observed in the patient sera a week after the administration. Pleural effusion was positive for the Ad in a week after the administration, which was judged by pleural fluid-mediated cytopathic effects to HEK293 cells, and remained continuously positive for Ad DNA for 7 weeks based on an assay with polymerase chain reactions. These data suggested that retention of Ad was much longer in an intrapleural injection than that in a systemic administration. Imaging techniques demonstrated tumor volume reduction in a few patients and such good responses in the imaging were linked with prolonged survival of the patients.
Ad-IFN-mediated effects were further investigated in the following reports.
11,12 An anti-Ad antibody level prior to the Clinical outcomes, progressive disease (PD) and stable disease (SD), were judged by the measurable tumor sizes.
Gene therapy for mesothelioma M Tagawa Neutralizing anti-Ad antibody was not yet produced on day 3, and the transduction level by the second injection was greater at 3-days interval than that at 7 days-interval. Administration of the multiple injections before boosting antibody formation is a way to increase the transgene expression. It is however practically difficult to inject Ad many times in a short period and thus an intrapleural injection has such a disadvantage in terms of gene transduction as found in intravenous injections. These clinical trials with replication-incompetent Ad collectively showed that intrapleural injection of Ad was safe and produced anti-tumor responses in some patients. The clinical benefits were not due to the direct cell killing but probably due to host immune responses. All the clinical trials with intrapleural Ad administration demonstrated generation of antibody that reacted with unidentified molecules in established mesothelioma cell lines, which may be associated with possible shared tumor antigens among mesothelioma. The clinical studies also detected activation of cytotoxic T and/or natural killer cells, but it is currently unclear as to the contribution of these cell-mediated responses to the clinical responses. Further investigations are required regarding a role of the activated immune responses in clinical benefits in the context of gene therapy.
IMMUNOTHERAPY AND MULTIMODAL TREATMENTS IN FUTURE
Significant tumors regression by Ad-mediated transgene expressions is currently unachievable and the precedent clinical studies for mesothelioma indicated that direct cytotoxic effects to tumors did not play a major role in producing clinical benefits. These studies rather suggested that activation of host defense mechanisms was one of the primary goals in Ad-mediated anti-tumor activities. It is therefore crucial whether antigen presenting cells can efficiently uptake a putative tumor antigen released through tumor cell death and coordinately present the antigen peptides to helper T cells. Generation of immune responses against tumor antigens followed by tumor cell death has been observed even with chemotherapy and radiotherapy. Nevertheless, gene therapy with a viral vector system has an advantage over such conventional treatments because gene therapy using viral vectors does not suppress host immune responses as commonly found in the conventional therapy but rather augments the immunity. There are several points to be considered for activation of an immune system with viral vectors. (1) Facilitated antigen uptake by professional antigen presenting cells: CD40 ligand and Fas ligand stimulate professional antigen presenting cells such as dendritic cells, which express the corresponding receptors, CD40 and Fas, respectively. Tumors transduced with the respective ligand genes can stimulate the antigen presenting cells through the receptor/ligand interactions and augment a presentation process of the tumor antigen(s). 45 Immune responses against tumors are generated at local regional lymph nodes such as hilar lymph nodes, subcarinal lymph nodes and mediastinal lymph nodes as found in lung cancer cases. It remains however uncharacterized whether tumors dying in the pleural cavity can efficiently stimulate the antigen processing in regional lymph nodes. The major disadvantage in enhancing host immunity with a viral vector is generation of anti-vector antibody. Biodistribution of the vectors administered in the pleural cavity is not currently well understood. Previous studies showed that Ad administered in the pleural cavity induced anti-Ad antibody production with the same kinetics as found in the case of systemic Ad administration, which suggests that majority of Ad administered in the pleural cavity may be absorbed into blood stream. Some of mesothelioma cases in fact showed elevated serum levels of hepatic enzymes after intrapleural Ad administrations and the Ad DNA was detected in the patient sera. Our preclinical data also indicated that liver became Ad DNA-positive after intrapleural administration. These data clearly indicated that Ad in the pleural cavity hematogenously migrated into liver. When Ad vectors are processed in a different manner from putative tumors antigens, modification of Ad to enhance the antigen processing ability of an endogenous tumor antigen but not exogenous viral antigens will be effective. If such a differential processing operates in vivo, efficacy of Ad enforced with ability to stimulate dendritic cells such as being armed with the CD40 ligand or the Fas ligand gene needs to be re-examined as to whether the modification does not hamper the processing. Combinatory use of gene therapy with a molecular target agent or an anti-cancer agent is an option for mesothelioma treatments. Few chemotherapeutic agents are effective for mesothelioma but the combination can expand the therapeutic utility of these agents that are not even effective alone. There are several points that need careful investigations in combination of gene therapy and chemical agents. (1) Viral gene expression: A molecular target agent or an anti-cancer agent can inhibit replication of oncolytic viruses since these agents suppress host cell proliferation and metabolism. The agents may also down-regulate the transgene expression by replication-incompetent viruses because the agents sometimes inhibit gene regulation at a transcriptional and/or a translational level, or influence degradation processes of the gene products. Nevertheless, an anti-cancer agent can augment cytotoxicity and produce synergism with viruses by activating its own cell death pathways. A number of factors positively or negatively influence the combinatory effects and these factors can be dependent on tumor cell types. For example, viral infection induces production of IFNs, which play a certain role in both antiviral responses and anti-tumor immunity, and the IFN production is controlled by various cellular factors such as expression levels of the IFN receptor complexes and induction levels of the signal transducer and activator of transcription family members. It is preferable to identify a biomarker to predict the efficacy of antitumor responses achieved by viruses and the combinatory usage. (2) Variable effects of a molecular target agent: Some of the signal transduction systems are constitutively activated in mesothelioma, and molecular target agents suppressing the activated systems are now tested for the therapeutic efficacy. These signaling systems are sometimes controlled by a number of conditions in non-tumorous tissues such as inflammation around the tumors and cell-to-cell interactions through extracellular matrixes and stroma cells. Therapeutic effects of the agents to inhibit the constitutively activated pathways are thereby influenced by elements outside of tumors and may be dependent on a local environment. An agent targeting the abnormal signaling pathway can thereby show different efficacy in in vivo settings than that assayed in vitro, and consequently the combinatory use may produce complex results in terms of in vivo effects.
CONCLUSIONS
Gene therapy can hold advantages over conventional therapeutics in mesothelioma treatments, and accumulating results on precedent clinical trials with replication-incompetent Ad showed that an intrapleural injection of Ad was safe and that gene transduction to mesothelioma through pleural effusion was possible. In contrast, an intrapleural Ad injection stimulated antibody production as rapidly as did a systemic Ad injection. Multiple administrations of Ad during a short interval can circumvent an antibody-mediated decreased transgene expression, but probably need an injection catheter kept at a chest wall, which may increase medical complications. At this moment, any clinical data with oncolytic viruses have not been published although some clinical studies with those vectors are now in progress. These studies will shed a new light on mesothelioma treatments because production of oncolytic viruses in the pleural cavity will produce a complex situation compared with nonreplication typed vectors. Retention of the produced viruses in the pleural cavity is beneficial to increase a constant contact with mesothelioma but raises the possibility of augmenting anti-viral antibody production. Gene medicine can open possibility of a combinatory use with a molecular target agent which is currently ineffective to mesothelioma as a single agent since mechanisms of anti-tumor effects by gene medicine are different from those of conventional chemotherapy. Multimodal treatments are absolutely required to improve the prognosis of mesothelioma patients and gene therapy, perhaps along with immunotherapy, can be one of the candidate modalities.
